Product Images Duloxetine Delayed-release
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 9 images provide visual information about the product associated with Duloxetine Delayed-release NDC 45865-815 by Medsource Pharmaceuticals, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
pdp - 815
Chemical Structure - duloxetine 01
Figure 1 - duloxetine 02
Figure 2 - duloxetine 03
This is a graph showing the proportion of patients who experienced a relapse while taking a placebo or duloxetine over a period of time. The x-axis represents the time from randomization to relapse in days, while the y-axis represents the proportion of patients experiencing relapse.*
Figure 3 - duloxetine 04
Figure 4 - duloxetine 05
Figure 7 - duloxetine 06
This is a chart that shows the percentage of patients improved in terms of pain relief. The x-axis shows the range of percentage improvement from 0 to 100 while the y-axis represents the treatment groups, one being the placebo while the other is DUL 601120 mg taken once daily. The chart shows that DUL was more effective in improving pain than the placebo.*
Figure 8 - duloxetine 07
This is a chart that shows the percentage of patients improved. The top row indicates a 100% improvement. The second row shows the percentage of improvement for both the placebo group and the group that received a 60mg daily dose of DUL. The remaining rows list numerical values for each subgroup. The chart also includes a section that shows the percentage improvement in pain from baseline, but it is not clear what the units of measurement or the source of the data are.*
Figure 9 - duloxetine 08
This table provides information about the percentage of patients with improved pain relief based on a base case. The percentage of improvement ranges from 0 to 100, with the highest percentage of improvement observed for patients using DUL 60/120 mg once daily. The table measures percentage improvement in pain from the baseline (BOCF).*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.